One more comment about SN-2310. It didn't produce the early-onset diarrhea that's one of the worst side effects of Irinotecan. So if it works, it would probably displace Irinotecan, which as I mentioned has around $1 billion in annual sales, pretty quickly. In preclinical tests it was much more effective than Irinotecan. So even though it didn't show much efficacy in the phase 1 trial, I suspect someone will be interested in licensing it.